The frequency of liver fibrosis and clinical symptoms in patients with opisthorchiasis


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Background. The importance of the problem of opisthorchiasis is dictated by the long-lasting disease duration with possible complications provoking the formation of periportal fibrosis, recurrent pancreatitis, cholecystitis, gallstone disease, and cholangiocarcinoma. Objective. The evaluation of clinical and biochemical manifestations in patients with chronic opisthorchiasis, depending on the severity of liver fibrosis (LF). Methods. 58 patients with chronic opisthorchiasis (33 men and 25 women; mean age - 42.3 years) and 25 healthy patients (14 men and 11 women; mean age - 41.5 years) aged 24 to 60 years were examined. Opisthorchiasis was diagnosed in all 58 patients by determining the eggs or bodies of adult parasites in duodenal contents and/or feces (according to the Kato technique). Clinical symptoms and medical history were studied using a standard questionnaire developed on the basis of current international classifications. To diagnose concomitant changes and complications, all patients underwent ultrasound examination of the liver and pancreas, and fibrogastroscopy. LF was studied in all 58 patients with opisthorchiasis by the elastometry using Aixplorer (France) or Siemens Acuson S2000 (Germany) ultrasound systems according to the METAVIR scale with 4 degrees of fibrosis. The control group was recruited from healthy individuals who did not present gastroenterological problems during the annual medical examination, did not have pronounced chronic diseases of various organs and systems, were characterized by normal clinical and biochemical blood tests, lack of viral hepatitis markers and antibodies to opisthorchis, and had no history of alcohol abuse. Results. The most common clinical manifestations of opisthorchiasis included astheno-vegetative syndrome (60.3%), right subcostal pain (34.5%) and pain in the lower abdomen associated with altered defecation pattern (17.2%). The systemic nature of the clinical manifestations of the studied parasitosis was indicated by a high frequency of articular syndrome (24.1%) and skin itching (25.9%). METAVIR F2 stage LF was registered in 20.7% of the examined individuals, and F3-F4 stage LF was detected in 17.2% of patients with opisthorchiasis. In opisthorchiasis patients, weekly right subcostal pain, bloating, skin itching, articular and asthenovegetative syndromes, hepatomegaly, and an increase in blood transaminase, alkaline phosphatase and total bilirubin levels were associated with severe LF. Conclusion. In patients with opisthorchiasis, clinical symptoms were clearly associated with the severity of LF. A significant proportion of patients with opisthorchiasis had biochemical equivalents of cytolytic and cholestatic syndromes, which indicates the presence of an aggressive inflammatory process in the liver. We found a high incidence of severe LF (METAVIR F2-F4 stage), which verifies the basic concept of our study. The project “Immuno-biochemical model for predicting the severity of precancerous changes in the liver in patients with chronic opisthorchiasis" was carried out with the support of the Krasnoyarsk Regional Fund for the Support of Scientific and Technical Activities (application code: 2019051404996).

Full Text

Restricted Access

About the authors

E. G Gorchilova

Private Healthcare Institution “Clinical Hospital “Russian Railways-Medicine" of the city of Krasnoyarsk"

Krasnoyarsk, Russia

Vladislav V. Tsukanov

Federal Research Center “Krasnoyarsk Scientific Center of the Siberian Branch of the Russian Academy of Sciences"

Email: gastro@impn.ru
Dr. Sci. (Med.), Professor, Head of the Clinical Department of Pathology of Digestive System in Adults and Children, Scientific Research Institute of Medical Problems of the North Krasnoyarsk, Russia

Yu. L Tonkikh

Federal Research Center “Krasnoyarsk Scientific Center of the Siberian Branch of the Russian Academy of Sciences"

Research Institute of Medical Problems of the North Krasnoyarsk, Russia

A. V Vasyutin

Federal Research Center “Krasnoyarsk Scientific Center of the Siberian Branch of the Russian Academy of Sciences"

Research Institute of Medical Problems of the North Krasnoyarsk, Russia

O. S Rzhavicheva

Private Healthcare Institution “Clinical Hospital “Russian Railways-Medicine" of the city of Krasnoyarsk"

Krasnoyarsk, Russia

References

  1. Цуканов В.В., Селиверстова Е.В., Догадин С.А. Показатели липидного состава сыворотки крови и желчи при заболеваниях желчевыводящих путей у больных сахарным диабетом. Терапевтический архив. 2005;77(2):15-8.
  2. Цуканов В.В., Тонких Ю.Л., Бронникова Е.П., Манчук В.Т Механизм нормолипидемии у северных народностей. Клиническая медицина. 1999;77(2):38-9.
  3. Sripa B, Jumnainsong A., Tangkawattana S., Haswell M.R. Immune Response to Opisthorchis viverrini Infection and Its Role in Pathology Adv Parasitol. 2018;102:73-95. Doi: 10.1016/ bs.apar.2018.08.003.
  4. Saltykova I.V, Petrov V.A., Logacheva M.D., et al. Biliary Microbiota, Gallstone Disease and Infection with Opisthorchis felineus. PLoS Negl Trop Dis. 2016;10(7):e0004809. doi: 10.1371/journal. pntd.0004809.
  5. Edwards S.W., Spofford E.M., Price C. et al. Opisthorchiasis-Induced Cholangiocarcinoma: How Innate Immunity May Cause Cancer. Adv Parasitol. 2018;101:149-76. Doi: 10.1016/ bs.apar.2018.05.006.
  6. Bouvard V., Baan R., Straif K. et al. A review of human carcinogens - Part B: biological agents. Lancet Oncol. 2009;10(4):321-22. doi: 10.1016/s1470-2045(09)70096-8.
  7. Максимова Г.А., Жукова Н.А., Кашина Е.В. и др. Роль Opisthorchis felineus в индукции рака желчных протоков. Паразитология. 2015;49(1):3-11.
  8. Fedorova O.S., Kovshirina Y.V., Kovshirina A.E., et al. Opisthorchis felineus infection and cholangiocarcinoma in the Russian Federation: A review of medical statistics. Parasitol Int. 2017;66(4):365-71. Doi: 10.1016/j. parint.2016.07.010
  9. Parkin D.M., Bray F., Ferlay J., Pisani P Global cancer statistics, 2002. CA Cancer J Clin. 2005; 55(2):74-108. doi: 10.3322/canjclin.55.2.74
  10. Poynard T., Bedossa P., Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet. 1997;349(9055):825-32. doi: 10.1016/s0140-6736(96)07642-8.
  11. McMahon B.J., Bruce M.G., Koch A., et al. The diagnosis and treatment of Helicobacter pylori infection in Arctic regions with a high prevalence of infection: Expert Commentary Epidemiol Infect. 2016;144(2):225-33. Doi: 10.1017/ S0950268815001181.
  12. Cappellesso R., Fassan M., Hanspeter E., et al. HER2 status in gastroesophageal cancer: a tissue microarray study of 1040 cases. Hum Pathol. 2015;46(5):665-72. Doi: 10.1016/j. humpath.2015.02.007.
  13. Штыгашева О.В., Цуканов В.В. Ассоциация Cаg A и Vac A штаммов Helicobacter pylori и язвенной болезни в организованной популяции г. Абакана. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2004;14(2):84-7.
  14. Цуканов В.В., Амельчугова О.С., Каспаров Э.В. и др. Роль эрадикации Helicobacter pylori в профилактике рака желудка. Терапевтический архив. 2014;86(8):124-27.

Supplementary files

Supplementary Files
Action
1. JATS XML

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies